Aura Biosciences (AURA) Total Non-Current Liabilities (2020 - 2022)
Aura Biosciences' (AURA) quarterly Total Non-Current Liabilities came in at $5.9 million in Q2 2022, up 12.56% on a QoQ basis from $5.2 million in Q1 2022.
Aura Biosciences (AURA) Total Non-Current Liabilities (2020 - 2022) Analysis & Trends
Aura Biosciences (AURA) has 3 years of Total Non-Current Liabilities data on file, last reported at $5.9 million in Q2 2022.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $5.9 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $5.9 million (changed N/A YoY) and the FY2021 annual result came in at $7.6 million, up 185.95% from the prior year.
- Total Non-Current Liabilities rose to $5.9 million in Q2 2022, from $5.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $7.6 million in Q4 2021 to a low of $2.7 million in Q4 2020.
- A 3-year average of $5.5 million and a median of $5.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 185.95% in 2021, down 185.95% in 2021.
- Tracing AURA's Total Non-Current Liabilities over 3 years: stood at $2.7 million in 2020, then surged by 185.95% to $7.6 million in 2021, then slipped by 23.18% to $5.9 million in 2022.
- The last three Total Non-Current Liabilities figures came in at $5.9 million (Q2 2022), $5.2 million (Q1 2022), and $7.6 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 5.86 Mn |
| Mar 31, 2022 | 5.21 Mn |
| Dec 31, 2021 | 7.63 Mn |
| Sep 30, 2021 | 6.34 Mn |
| Dec 31, 2020 | 2.67 Mn |